Calcitonin gene related peptide (CGRP) has been proposed to contribute to pain transmission and inflammation and for these reasons to the mechanism of migraine. CGRP is, in fact, expressed in and released from a subset of polymodal primary sensory neurons of the trigeminal ganglion. Release of CGRP in the dorsal spinal cord has been associated to nociceptive transmission, and release from perivascular nerve endings causes neurogenic vasodilatation. CGRP levels increase in the cranial circulation during migraine attacks, and GRP injection in migraineurs results in migraine-like attacks. Most importantly, two chemically unrelated CGRP-receptor antagonists, the parenteral agent, olcegepant, and the orally available telcagepant demonstrated efficacy in the treatment of migraine attacks, thus supporting CGRP as an important mediator in migraine.

CGRP receptors in the control of pain and inflammation / Silvia Benemei; Paola Nicoletti; Jay G Capone; Pierangelo Geppetti. - In: CURRENT OPINION IN PHARMACOLOGY. - ISSN 1471-4892. - ELETTRONICO. - 9:(2009), pp. 9-14. [10.1016/j.coph.2008.12.007]

CGRP receptors in the control of pain and inflammation

BENEMEI, SILVIA;NICOLETTI, PAOLA;GEPPETTI, PIERANGELO
2009

Abstract

Calcitonin gene related peptide (CGRP) has been proposed to contribute to pain transmission and inflammation and for these reasons to the mechanism of migraine. CGRP is, in fact, expressed in and released from a subset of polymodal primary sensory neurons of the trigeminal ganglion. Release of CGRP in the dorsal spinal cord has been associated to nociceptive transmission, and release from perivascular nerve endings causes neurogenic vasodilatation. CGRP levels increase in the cranial circulation during migraine attacks, and GRP injection in migraineurs results in migraine-like attacks. Most importantly, two chemically unrelated CGRP-receptor antagonists, the parenteral agent, olcegepant, and the orally available telcagepant demonstrated efficacy in the treatment of migraine attacks, thus supporting CGRP as an important mediator in migraine.
9
9
14
Silvia Benemei; Paola Nicoletti; Jay G Capone; Pierangelo Geppetti
File in questo prodotto:
File Dimensione Formato  
Benemei, Curr Opin Pharmacol 2009.pdf

Accesso chiuso

Descrizione: Articolo principale
Tipologia: Pdf editoriale (Version of record)
Licenza: DRM non definito
Dimensione 262.77 kB
Formato Adobe PDF
262.77 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/351133
Citazioni
  • ???jsp.display-item.citation.pmc??? 57
  • Scopus 133
  • ???jsp.display-item.citation.isi??? 132
social impact